Výsledky vyhledávání - "Andy Boshier"

Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry

Autor: Joseph K. Park, Troy E. Barger, June Kim, David J. Kuter, Vibha Jawa, Andy Boshier, Daniel T. Mytych

Publikováno v: British Journal of Haematology

Summary Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242a0d19611b4c500a82f239b3cc500
https://pubmed.ncbi.nlm.nih.gov/32311075

Zobrazit plný text záznamu

Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study

Autor: Louise Taylor, Anouchka Seesaghur, Martin R. Schipperus, Georgia Kaiafa, Georg Kreuzbauer, Sally Wetten, Andy Boshier

Publikováno v: Drug Safety

Introduction Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopeni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c613ea46a4c680442216f3f1de0293d
https://doi.org/10.1007/s40264-018-0723-6

Zobrazit plný text záznamu

Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry

Autor: Andy Boshier, Joseph K. Park, David J. Kuter, June Kim, Troy E. Barger, Vibha Jawa, Daniel T. Mytych

Publikováno v: Blood. 132:2427-2427

Background: Romiplostim (Nplate®) is a thrombopoietin (TPO) receptor agonist approved for the treatment of adult chronic immune thrombocytopenia (ITP). The formation of antibodies (Abs) against romiplostim may lead to a loss of response, and a theor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6cad3e89f6bed71830dd5fae56c1dc1f
https://doi.org/10.1182/blood-2018-99-113484

Zobrazit plný text záznamu

Assessment of Self-Administration of Romiplostim after Receipt of Home Administration Training Materials: A Cross-Sectional Study of Patients with Immune Thrombocytopenic Purpura and Caregivers

Autor: Anouchka Seesaghur, Andy Boshier, Sally Wetten, Georgia Kaiafa, James Bennett, Martin R. Schipperus, Georg Kreuzbauer, Louise Taylor

Publikováno v: Blood. 128:4918-4918

Background: Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved for use in the EU for adult patients with chronic immune thrombocytopenia (ITP) refractory to other treatments. Initially approved for administration by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ed948c96ca809c4bd7580808a00ee79
https://doi.org/10.1182/blood.v128.22.4918.4918

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání